This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
The purpose of the study is to explore the efficacy and safety of HBLPADD Coil Deep TMS in subjects with ADHD. The Patient Population is 40 patients diagnosed with ADHD. The patients will be of all racial, ethnic and gender categories, ranging from 18 to 65 years of age.
The Structure of The study is a randomized, prospective, 5 weeks, double blind study. The treatment administrator and the study personnel and patients will be masked to the treatment being administrated. The study group will receive active Deep TMS treatment and the control group will receive an inactive, sham treatment.
The Primary Outcome Measure is will be examined by the change in the CAARS questionnaire from the baseline visit to the termination visit in the treatment group compared to the control group.
Principal Investigator: Prof. Hilik Levkovitz